MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
4.570
-2.160
-32.10%
After Hours: 4.520 -0.05 -1.09% 19:58 05/15 EDT
OPEN
4.390
PREV CLOSE
6.73
HIGH
5.40
LOW
4.100
VOLUME
745.09K
TURNOVER
--
52 WEEK HIGH
17.94
52 WEEK LOW
3.350
MARKET CAP
99.70M
P/E (TTM)
-1.4235
1D
5D
1M
3M
1Y
5Y
1D
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
TipRanks · 1d ago
Aardvark plummets on FDA clinical hold on Prader-Willi Syndrome asset
Seeking Alpha · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark
Reuters · 1d ago
Aardvark Therapeutics Is Maintained at Buy by B. Riley Securities
Dow Jones · 1d ago
Aardvark Therapeutics Price Target Cut to $7.00/Share From $8.00 by B. Riley Securities
Dow Jones · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 1d ago
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7
Benzinga · 1d ago
This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Benzinga · 1d ago
More
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.